Dose of Remi in Children

Determination of the 50% and 95% Effective Dose of Remimazolam for Intravenous Anesthesia Induction in Pediatric Patients

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05990673

Acronym

DRINK

Enrollment

Registered

2023-08-14

Start date

2023-08-10

Completion date

2023-09-10

Last updated

2023-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia

Keywords

general anesthesia, anesthesia induction, remimazolam

Brief summary

Remimazolam has demonstrated the potential as a valuable medication for procedural sedation and general anesthesia. However, the effective dosage of remimazolam in pediatric patients is still unknown.

Interventions

DRUGRemimazolam

remimazolam is given intravenously

Study design

Allocation

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

3 Years to 12 Years

Healthy volunteers

Inclusion criteria

* age from 3 to 12 years old * patients scheduled for surgery under general anesthesia

Exclusion criteria

* American Society of Anesthesiologists status \>=Ⅲ * Body mass index\>=28kg/m2 * patients who cannot cooperate with intravenous anesthesia induction * patients with risk of difficult airway * patients who are allergic to benzodiazepines * patients with delayed neurologic function

Design outcomes

Primary

Measure	Time frame	Description
half effective dosage	from injection of remimazolam to loss of consciousness, at an average of 5 minutes	the dosage by which half of the patients will be sedated

Secondary

Measure	Time frame	Description
95% effective dosage	from injection of remimazolam to loss of consciousness, at an average of 5 minutes	the dosage by which 95% of the patients will be sedated

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026